UB Paderborn / Katalog / Suche / in CDI

Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation

European journal of clinical pharmacology, 2022-06, Vol.78 (6), p.1047-1048

De Mey, Christian Martin

2022

Volltextzugriff (PDF)

Effects of renal insufficiency on the elimination of fluorescein lisicol (NRL972), an investigational marker of hepatic transporter function

International journal of clinical pharmacology and therapeutics, 2015-07, Vol.53 (7), p.523

2015

Volltextzugriff (PDF)

Ocular safety of propiverine hydrochloride in elderly patients with primary open- and narrow-angle glaucoma

International journal of clinical pharmacology and therapeutics, 2016-12, Vol.54 (12), p.977

2016

Volltextzugriff (PDF)

Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine

International journal of clinical pharmacology and therapeutics, 2015-03, Vol.53 (3), p.247

2015

Volltextzugriff (PDF)

Effects of Hepatic Dysfunction on the Single-Dose Pharmacokinetics of Fesoterodine

Journal of clinical pharmacology, 2011-03, Vol.51 (3), p.397-405

2011

Volltextzugriff (PDF)

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2022-01, Vol.36 (1), p.41-53

2022

Volltextzugriff (PDF)

Abstract 301: Pleiotropic Effects of Ginkgo Biloba: Implication in Blood Pressure Regulation

Hypertension (Dallas, Tex. 1979), 2012-09, Vol.60 (suppl_1)

2012

Volltextzugriff (PDF)

α1-Blocker Therapy for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: What Are the Relevant Differences in Randomised Controlled Trials?

European urology, 2000, Vol.38 (1), p.25-39

De Mey, Christian

2000

Volltextzugriff (PDF)

Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis

Clinical pharmacokinetics, 2007-01, Vol.46 (5), p.403-416

2007

Volltextzugriff (PDF)

Sinn und Unsinn von Anwendungsbeobachtungen

Medizinische Klinik (München. 1983), 2000-01, Vol.95 (1), p.56-62

de Mey, Christian

2000

Volltextzugriff (PDF)

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men

Clinical pharmacology and therapeutics, 1996-01, Vol.59 (1), p.72-82

1996

Volltextzugriff (PDF)

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers

Clinical pharmacology and therapeutics, 1992-12, Vol.52 (6), p.609-619

1992

Volltextzugriff (PDF)

Cardiovascular Effects of Alpha-Blockers Used for the Treatment of Symptomatic BPH: Impact on Safety and Well-Being

European urology, 1998, Vol.34 (2), p.18-28

de Mey, Christian

1998

Volltextzugriff (PDF)

α1-Blockers for BPH: Are There Differences?

European urology, 1999, Vol.36 (3), p.52-63

de Mey, Christian

1999

Volltextzugriff (PDF)

Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans

Clinical pharmacology and therapeutics, 2001-08, Vol.70 (2), p.142-148

2001

Volltextzugriff (PDF)

Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis -Alternatives to Sildenafil Citrate

Current medical research and opinion, 1998, Vol.14 (4), p.187-202

de Mey, Christian

1998

Volltextzugriff (PDF)

Effect of Age and Spontaneous Hypertension on the Tachyphylaxis to 5-Hydroxytryptamine and Angiotensin II in the Isolated Rat Kidney

Hypertension (Dallas, Tex. 1979), 1981-11, Vol.3 (6), p.718-724

1981

Volltextzugriff (PDF)

Dose‐effect and pharmacokinetic‐pharmacodynamic relationships of the β1adrenergic receptor blocking properties of various doses of carvedilol in healthy humans

Clinical pharmacology and therapeutics, 1994-03, Vol.55 (3), p.329-337

1994

Volltextzugriff (PDF)

Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency

Arzneimittel-Forschung, 2003-01, Vol.53 (11), p.769

2003

Volltextzugriff (PDF)

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

BMC clinical pharmacology, 2011-06, Vol.11 (1), p.7-7, Article 7

2011

Volltextzugriff (PDF)

Reliability of screening procedures in identifying subjects suitable for enrollment in clinical pharmacology studies

Clinical pharmacology and therapeutics, 1997-07, Vol.62 (1), p.112-113

Mey, Christian

1997

Volltextzugriff (PDF)

Influence of the dopamine agonist α-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease

Clinical neuropharmacology, 2001-07, Vol.24 (4), p.235-238

2001

Volltextzugriff (PDF)

Differential vascular α1‐adrenoceptor antagonism by tamsulosin and terazosin

British journal of clinical pharmacology, 1999-01, Vol.47 (1), p.67-74

1999

Volltextzugriff (PDF)

Continuous Measurement of Hemodynamic Alterations During Pharmacologic Cardiovascular Stress Using Automated Impedance Cardiography

Journal of clinical pharmacology, 1997-01, Vol.37 (S1), p.21S-28S

1997

Volltextzugriff (PDF)

Usefulness, Usability, and Quality Criteria for Noninvasive Methods in Cardiovascular Clinical Pharmacology

Journal of clinical pharmacology, 1997-01, Vol.37 (S1), p.11S-20S

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase I studies in EU: due change in compliance and transparency under the EU clinical trials regulation

Effects of renal insufficiency on the elimination of fluorescein lisicol (NRL972), an investigational marker of hepatic transporter function

Ocular safety of propiverine hydrochloride in elderly patients with primary open- and narrow-angle glaucoma

Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine

Effects of Hepatic Dysfunction on the Single-Dose Pharmacokinetics of Fesoterodine

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

Abstract 301: Pleiotropic Effects of Ginkgo Biloba: Implication in Blood Pressure Regulation

α1-Blocker Therapy for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: What Are the Relevant Differences in Randomised Controlled Trials?

Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis

Sinn und Unsinn von Anwendungsbeobachtungen

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers

Cardiovascular Effects of Alpha-Blockers Used for the Treatment of Symptomatic BPH: Impact on Safety and Well-Being

α1-Blockers for BPH: Are There Differences?

Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans

Opportunities for the Treatment of Erectile Dysfunction by Modulation of the NO Axis -Alternatives to Sildenafil Citrate

Effect of Age and Spontaneous Hypertension on the Tachyphylaxis to 5-Hydroxytryptamine and Angiotensin II in the Isolated Rat Kidney

Dose‐effect and pharmacokinetic‐pharmacodynamic relationships of the β1adrenergic receptor blocking properties of various doses of carvedilol in healthy humans

Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

Reliability of screening procedures in identifying subjects suitable for enrollment in clinical pharmacology studies

Influence of the dopamine agonist α-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease

Differential vascular α1‐adrenoceptor antagonism by tamsulosin and terazosin

Continuous Measurement of Hemodynamic Alterations During Pharmacologic Cardiovascular Stress Using Automated Impedance Cardiography

Usefulness, Usability, and Quality Criteria for Noninvasive Methods in Cardiovascular Clinical Pharmacology

Suchergebnisse filtern